SEC Form 10-Q filed by TransMedics Group Inc.
Unavailable
Unavailable
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/21/2024 | $208.00 | Buy | Needham |
6/6/2024 | $161.00 | Overweight | Cantor Fitzgerald |
6/4/2024 | $151.00 | Overweight | Stephens |
3/28/2024 | $95.00 | Overweight | Piper Sandler |
7/19/2023 | Outperform | Robert W. Baird | |
8/2/2022 | $48.00 | Neutral → Overweight | JP Morgan |
2/25/2022 | $22.00 → $15.00 | Equal-Weight | Morgan Stanley |
1/7/2022 | $33.00 → $22.00 | Equal-Weight | Morgan Stanley |
TransMedics Gr (NASDAQ:TMDX) has outperformed the market over the past 5 years by 30.55% on an annualized basis producing an average annual return of 43.06%. Currently, TransMedics Gr has a market capitalization of $5.09 billion. Buying $1000 In TMDX: If an investor had bought $1000 of TMDX stock 5 years ago, it would be worth $5,892.80 today based on a price of $154.60 for TMDX at the time of writing. TransMedics Gr's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated con
TransMedics Gr (NASDAQ:TMDX) has outperformed the market over the past 5 years by 27.68% on an annualized basis producing an average annual return of 41.28%. Currently, TransMedics Gr has a market capitalization of $4.75 billion. Buying $100 In TMDX: If an investor had bought $100 of TMDX stock 5 years ago, it would be worth $587.32 today based on a price of $144.09 for TMDX at the time of writing. TransMedics Gr's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content
Morgan Stanley analyst Patrick Wood maintains TransMedics Gr (NASDAQ:TMDX) with a Equal-Weight and raises the price target from $104 to $145.
Needham initiated coverage of TransMedics Group with a rating of Buy and set a new price target of $208.00
Cantor Fitzgerald initiated coverage of TransMedics Group with a rating of Overweight and set a new price target of $161.00
Stephens initiated coverage of TransMedics Group with a rating of Overweight and set a new price target of $151.00
8-K - TransMedics Group, Inc. (0001756262) (Filer)
144 - TransMedics Group, Inc. (0001756262) (Subject)
144 - TransMedics Group, Inc. (0001756262) (Subject)
ANDOVER, Mass., Aug. 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York. The fireside chat will take place on Wednesday, September 4, 2024, at 1:05 p.m. Eastern Time. Event: Morgan Stanley 22nd Annual Global Healthcare Confere
ANDOVER, Mass., Aug. 20, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on August 16, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 3,073 shares of its common stock and an aggregate of 2,003 restricted stock units to 4 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4)
ANDOVER, Mass., July 31, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $114.3 million in the second quarter of 2024, a 118% increase compared to the second quarter of 2023Generated net income of $12.2 million or $0.35 per diluted share in the second quarter of 2024Owned 15 total aircraft as of June 30, 2024Purc
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
ANDOVER, Mass., July 31, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $114.3 million in the second quarter of 2024, a 118% increase compared to the second quarter of 2023Generated net income of $12.2 million or $0.35 per diluted share in the second quarter of 2024Owned 15 total aircraft as of June 30, 2024Purc
ANDOVER, Mass., July 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for dome
ANDOVER, Mass., April 30, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Net revenue of $96.9 million in the first quarter of 2024, a 133% increase compared to the first quarter of 2023Generated net income of $12.2 million or $0.35 per fully diluted share in the first quarter of 2024OCS Heart and OCS Lung and associated new cli
ANDOVER, Mass., July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary. "We are excited to welcome Anil to the TransMedics leadership team," said Waleed Hassanein, MD, President and Chief Executive Officer. "Anil brings a wealth of healthcare industry experience, and his knowledge and counsel will be
ANDOVER, Mass., Feb. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Nick Corcoran as Senior Vice President of Supply Chain and Operations, effective immediately. "Nick has extensive end-to-end supply chain and operations experience making him the perfect fit for TransMedics as we expand our operations to meet the growing global demand for OCS products and service," said Waleed H
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo